Wayland Provides Clarification on Recent German Tender Update

TORONTO, April 18, 2019 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) would like to expand on the update that the Company provided to the market on April 17, 2019 with respect to the ongoing process for domestic cultivation of medical cannabis in Germany (“the Update”).

The Company would like to clarify that Wayland’s joint venture with DEMECAN GmbH (“DEMECAN”) received a score of 60/60 for quality and 40/40 for pricing in the original tender process from early in 2018. Notwithstanding the challenge to the most current tenders described in the Update, the Company is confident that DEMECAN will be successful, and will be awarded the 3 lots for production.

About Wayland Group

Wayland is a vertically integrated cultivator and processor of cannabis. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a cannabis cultivation, extraction, formulation, and distribution business under federal licenses from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland and, Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia, and Argentina, in its effort to enhance lives through cannabis.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Wayland, please visit our website at www.waylandgroup.com

Contact Information:
Investor Relations
Graham Farrell
VP, Communications

Media Inquiries: media@waylandgroup.com

Corporate Headquarters (Canada)
Wayland Group Corp. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3

European Headquarters (Germany)
c/o Wayland
Max Joseph Str. 7
80333 Munich